Portopulmonary Hypertension Treated by Occlusion of a Spontaneous Portosystemic Shunt Followed by Endothelin Receptor Antagonist Administration

被引：1
|
作者：
Ishikawa, Tsuyoshi [1 ]
Kawamoto, Daiki [1 ]
Nishimura, Tatsuro [1 ]
Suetomi, Takeshi [2 ]
Kobayashi, Shigeki [3 ]
Takami, Taro [1 ]
机构：
[1] Yamaguchi Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, 1-1-1 Minami Kogushi, Ube, Yamaguchi 7558505, Japan
[2] Yamaguchi Univ, Grad Sch Med, Dept Med & Clin Sci, Ube, Yamaguchi, Japan
[3] Yamaguchi Univ, Sch Med, Dept Therapeut Sci Heart Failure Elderly, Ube, Yamaguchi, Japan
来源：
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY | 2024年 / 35卷 / 02期
关键词：
D O I：
10.1016/j.jvir.2023.10.028
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：313 / 315
页数：3
相关论文
共 50 条
  • [31] A case of extrahepatic portosystemic shunt without portal hypertension treated by laparoscopically assisted embolization
    Sato, T
    Asanuma, Y
    Ishida, H
    Hashimoto, M
    Tanaka, J
    Andoh, H
    Yasui, O
    Kurokawa, T
    Komatsuda, T
    Konno, K
    Heianna, J
    Koyama, K
    SURGERY, 1999, 126 (05) : 984 - 986
  • [32] Idiopathic myelofibrosis complicated by portal hypertension treated with a transjugular intrahepatic portosystemic shunt (TIPS)
    Belohlávek, J
    Schwarz, J
    Jirásek, A
    Krajina, A
    Polák, F
    Hruby, M
    WIENER KLINISCHE WOCHENSCHRIFT, 2001, 113 (5-6) : 208 - 211
  • [33] Endothelin receptor antagonist therapy in congenital heart disease with shunt-associated pulmonary arterial hypertension: A qualitative systematic review
    Fine, Nowell
    Dias, Bryan
    Shoemaker, Gerard
    Mehta, Sanjay
    CANADIAN JOURNAL OF CARDIOLOGY, 2009, 25 (03) : E63 - E68
  • [34] LU 135252: an endothelin a receptor antagonist for treatment of hypertension, dose response, efficacy and safety. The HEAT study: Hypertension, Endothelin Antagonist Treatment
    Nakov, R
    Pfarr, E
    Eberle, S
    EUROPEAN HEART JOURNAL, 2001, 22 : 611 - 611
  • [35] Safety and efficacy of the endothelin receptor antagonist macitentan in pediatric pulmonary hypertension
    Schweintzger, Sabrina
    Koestenberger, Martin
    Schlagenhauf, Axel
    Grangl, Gernot
    Burmas, Ante
    Kurath-Koller, Stefan
    Pocivalnik, Mirjam
    Sallmon, Hannes
    Baumgartner, Daniela
    Hansmann, Georg
    Gamillscheg, Andreas
    CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2020, 10 (05) : 1675 - 1685
  • [36] Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study
    Paul, GA
    Strange, J
    Wilkins, MR
    Stefanidis, A
    Mohiaddin, R
    Pennell, D
    Nihoyannopoulos, P
    Gibbs, JSR
    CIRCULATION, 2004, 110 (17) : 296 - 296
  • [37] Role of the endothelin receptor antagonist bosentan in the treatment of patients with pulmonary hypertension
    Tsareva, N. A.
    TERAPEVTICHESKII ARKHIV, 2013, 85 (12) : 127 - 136
  • [38] Ambrisentan -: Treatment of pulmonary arterial hypertension endothelin ETA receptor antagonist
    Sorbera, LA
    Castañer, J
    DRUGS OF THE FUTURE, 2005, 30 (08) : 765 - 770
  • [39] Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study
    Wilkins, MR
    Paul, GA
    Strange, JW
    Tunariu, N
    Gin-Sing, W
    Banya, WA
    Westwood, MA
    Stefanidis, A
    Ng, LL
    Pennell, DJ
    Mohiaddin, RH
    Nihoyannopoulos, P
    Gibbs, JSR
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 171 (11) : 1292 - 1297
  • [40] EFFECTS OF AN ENDOTHELIN RECEPTOR ANTAGONIST IN RATS WITH CYCLOSPORINE-INDUCED HYPERTENSION
    TAKEDA, Y
    MIYAMORI, I
    WU, PS
    YONEDA, T
    FURUKAWA, K
    TAKEDA, R
    HYPERTENSION, 1995, 26 (06) : 932 - 936
12345